Premium
A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis
Author(s) -
Brook S.,
Berk M.,
Selemani S.,
Kolloori J.,
Nzo I.
Publication year - 1998
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/(sici)1099-1077(199801)13:1<17::aid-hup937>3.0.co;2-g
Subject(s) - brief psychiatric rating scale , haloperidol , tolerability , schizophreniform disorder , psychosis , randomized controlled trial , rating scale , double blind , psychiatry , psychology , schizophrenia (object oriented programming) , acute psychosis , medicine , anesthesia , adverse effect , placebo , schizoaffective disorder , developmental psychology , alternative medicine , pathology , dopamine
This study is a double blind randomized controlled trial comparing zuclopenthixol acetate to haloperidol administered parenterally initially and followed by oral medication for 28 days in the treatment of acute psychosis. The sample included 44 patients with schizophrenia, schizophreniform disorder and substance‐induced psychotic disorder who required acute neuroleptic treatment. The patients were assessed using the Brief Psychiatric Rating Scale (BPRS), Clinical Global Improvement Scale (CGI) and the Simpson Angus Scale (SAS). While patients in both groups improved on all outcome measures, there was no significant differences between the two agents in terms of either efficacy or tolerability. © 1998 John Wiley & Sons, Ltd.